The Food and Drug Administration has approved an FDA-approved treatment for an estimated 30 million patients worldwide with severe, intractable, or relapsing-remitting cancer.
The approval, which is effective Jan. 1, is a significant victory for eclamptive therapy for patients with advanced, life-threatening, or incurable cancer.
The FDA says eclamsia is approved for patients who have been diagnosed with advanced cancer, those with relapsering-remission disease (RRD), and those with the rare but aggressive form of colorectal cancer.
“This medication has been approved for the treatment of intractability, relapser-remittances, and colorecectal cancers,” said Dr. Thomas B. Anderson, chief medical officer at the FDA.
“It is also a great addition to our treatment of patients with relapsed cancer and those who are on medication for other cancers.”
The approval also comes as the U.S. government seeks to expand its use of the drug.
It has used it in a number of cancer studies to help people who have not responded to other drugs or surgery.
In April, the U